Skip to main content

Prelude Therapeutics Incorporat (PRLD) Stock

Prelude Therapeutics Incorporat Stock Details, Movements and Public Alerts

Stock Details

Prelude Therapeutics Incorporat (PRLD), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $4.97. Over the past 52 weeks, it has ranged between $0.75 and $5.69. This places the current price at 87.3% of its 52-week high and 562.7% above its 52-week low. Recent trading volume was recorded at 320,070. The 14-day Relative Strength Index (RSI) stands at 60.61, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $4.41 by 12.70%. Similarly, it is above its 200-day moving average of $2.82 by 76.24%. The MACD histogram is 0.09, indicating bullish momentum (MACD Line: 0.20, Signal Line: 0.11). There is currently 1 active alert set for PRLD by users.

52-Week Range

$5.69 - $0.75

-12.65% from high · +562.67% from low

Avg Daily Volume

555,173

20-day average

100-day avg: 408,991

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-5.31

Price to Book

6.84

EV/EBITDA

-5.31

EPS (TTM)

-$1.00

Price to Sales

23.77

Beta

0.95

Less volatile than market

Q:How is PRLD valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is PRLD's risk profile compared to the market?
With a beta of 0.95, Prelude Therapeutics Incorporat is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 6.84 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

-309.54%

EBITDA

$-81,170,000

Return on Equity

-95.25%

Return on Assets

-39.69%

Q:How profitable and efficient is PRLD's business model?
0 The operating margin of -309.54% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -95.25% and ROA at -39.69%, the company achieves moderate returns on invested capital.
Q:What are PRLD's recent growth trends?
Growth data is not available for this stock.

Company Size & Market

Market Cap

$397.4M

Revenue (TTM)

$16.72M

Revenue/Share (TTM)

$0.21

Shares Outstanding

64.92M

Book Value/Share

$0.73

Asset Type

EQUITY

Q:What is PRLD's market capitalization and position?
Prelude Therapeutics Incorporat has a market capitalization of $397.4M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 64.92M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does PRLD's price compare to its book value?
Prelude Therapeutics Incorporat's book value per share is $0.73, while the current stock price is $4.97, resulting in a price-to-book (P/B) ratio of 6.82. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$8.00

60.97% upside potential

Analyst Recommendations

Strong Buy

1

Buy

2

Hold

0

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for PRLD?
3 analysts cover PRLD with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $8.00 implies 61.0% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on PRLD?
Current analyst recommendations:1 Strong Buy, 2 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jul 7, 2026, 02:12 AM

Technical Indicators

RSI (14-day)

60.61

Neutral

50-Day Moving Average

$4.41

12.70% above MA-50

200-Day Moving Average

$2.82

76.24% above MA-200

MACD Line

0.20

MACD Signal

0.11

MACD Histogram

0.09

Bullish

Q:What does PRLD's RSI value tell investors?
The RSI (Relative Strength Index) for PRLD is currently 60.61, indicating the stock is showing bullish momentum (60-70 range). The stock has positive momentum without being extremely overbought. This zone often occurs during healthy uptrends where buyers remain in control. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret PRLD's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.20 above the signal line at 0.11, with histogram at 0.09. This bullish crossover suggests upward momentum is building. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($4.41) is above the 200-day MA ($2.82), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Jul 7, 2026, 12:49 AM

Active Alerts

Alert Condition
RSI Threshold Cross
Threshold
70
Created
Jul 1, 2026, 04:23 PM

Stay Ahead of the Market with Prelude Therapeutics Incorporat Alerts

Set up price alerts for Prelude Therapeutics Incorporat and get notified instantly when the price hits your target. Never miss an important price movement again.